Nalgoova Therapeutics has joined Biopôle’s Vanguard Accelerator as it enters a new phase of development, moving from early validation toward clinical execution and market preparation.

Run by Biopôle in collaboration with Swiss Healthcare Startups, the six-month Vanguard Accelerator supports digital health ventures at critical growth stages. It links start-ups with a network of industry and healthcare experts who provide practical, real-time feedback to help accelerate clinical and commercial adoption of their technologies.

For Nalgoova – a start-up seeking to transform migraine care from generalised symptom management to precise, patient-specific treatment – the programme’s execution focus was a key draw. ‘What we value most is the emphasis on rapid, iterative progress through direct interaction with a multidisciplinary network of experts,’ says Dr Marzia Massignani, GM. ‘It stood out for its strong focus on interaction and execution, and its ability to connect start-ups with the right expertise at the right moment.’

The programme is helping Nalgoova validate key assumptions and align with real-world requirements. ‘We have already benefited from exchanges with specialists in quality and reimbursement, which have provided us with highly actionable insights to refine our regulatory and market access strategy,’ Massignani notes. ‘This kind of targeted, expert-driven feedback is essential as we build a spatial pain intelligence platform combining hardware, software and a clinical workflow.’

Nalgoova is developing a targeted, minimally invasive interventional solution for severe craniofacial pain conditions, including trigeminal neuralgia, refractory facial pain syndromes and migraines. Positioned between long-term pharmacological treatment and invasive neurosurgery, its approach uses precise anatomical guidance and tailored procedural targeting to address specific pain pathways, reducing pain intensity, attack frequency and reliance on medication.

Joining the Vanguard Accelerator at this stage reflects Nalgoova’s need for depth as well as speed. ‘We were looking for an environment that enables fast learning cycles and meaningful, actionable feedback, rather than purely advisory support,’ says Dr Massignani. ‘It’s about confronting both our technology and business model with diverse expert perspectives, identifying critical gaps early and making informed decisions quickly.’

Biopôle’s campus further strengthens this process through proximity to partners and expertise. ‘Being based at Biopôle gives us direct access to a highly integrated life sciences ecosystem,’ Dr Massignani says. ‘This allows us to shorten feedback loops, test assumptions in real-world settings and build the partnerships needed to bring our solution to market.’

Nalgoova joins a growing cohort of Vanguard Accelerator past participants – including CHD, MoleSense, Undae Science and DigeHealth – working to translate digital health innovation into practice. With early insights shaping its regulatory and clinical strategy, the company is advancing toward a market-ready solution and building the partnerships needed to deliver an innovative approach to treating severe facial pain.